David Deng

Corporate Officer/Principal presso Verinata Health, Inc.

Consumer Services

Health Technology

Health Services

Profilo

David Deng is currently working as the Director of Assay Development at Verinata Health, Inc. Previously, he worked as a Principal at Agilent Technologies, Inc. Dr. Deng holds a doctorate degree from McGill University and undergraduate, graduate, and doctorate degrees from Shanghai Jiao Tong University.

Posizioni attive di David Deng

Società	Posizione	Inizio
Verinata Health, Inc. Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA.	Corporate Officer/Principal	11/08/2009

Tutte le posizioni attive di David Deng

Precedenti posizioni note di David Deng

Società	Posizione	Fine
AGILENT TECHNOLOGIES, INC.	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di David Deng

Formazione di David Deng

McGill University	Doctorate Degree
Shanghai Jiao Tong University	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di David Deng

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
AGILENT TECHNOLOGIES, INC.	Health Technology

Aziende private	1
Verinata Health, Inc. Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA.	Health Services